Literature DB >> 32060903

Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model.

Vandana S Nikam1, Sandeep Nikam1, Akyl Sydykov2, Katrin Ahlbrecht1,2, Rory E Morty1, Werner Seeger1,2, Robert Voswinckel1,2.   

Abstract

BACKGROUND AND
PURPOSE: Recruitment and involvement of bone-/blood-derived circulating fibrocytes (CF) in the promotion of fibrotic tissue remodelling processes have been shown. However, their direct contribution to pathological changes is not clear. The present study investigates the causal role of CF in the pathogenesis of pulmonary hypertension (PH). EXPERIMENTAL APPROACH: For selective ablation of CF, we applied the suicidal gene strategy with herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir. The transgenic mice were generated, having HSV-TK-GFP transgene under the collagen 1 promoter. To selectively target CF, HSV-TK-GFP+ bone marrow transplanted into irradiated wild type mice. These chimera mice were subjected to hypoxia for PH induction and ganciclovir for CF ablation. KEY
RESULTS: In vivo CF ablation reduced right ventricular hypertrophy and vascular remodelling with reduced total collagen content. We quantified the CF recruited in the perivascular area and arterial wall of small pulmonary arteries. There was significant recruitment of CF in the lung in response to hypoxia. The characterization of CF showed the expression of CD45 and collagen1 (GFP) along with α-smooth muscle actin (αSMA). CONCLUSION AND IMPLICATIONS: Our data demonstrated that CF ablation has a potential impact on right ventricular hypertrophy and vascular remodelling in the setting of experimental pulmonary hypertension induced by hypoxia. The beneficial effects may be related to the direct contribution of fibrocytes or its paracrine effect on other resident cell types. Thus, clinical manipulation of CF may represent a novel therapeutic approach to ameliorate the disease state in pulmonary hypertension.
© 2020 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2020        PMID: 32060903      PMCID: PMC7279988          DOI: 10.1111/bph.15025

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  66 in total

1.  Conditional clara cell ablation reveals a self-renewing progenitor function of pulmonary neuroendocrine cells.

Authors:  S D Reynolds; K U Hong; A Giangreco; G W Mango; C Guron; Y Morimoto; B R Stripp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2000-06       Impact factor: 5.464

2.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

3.  Lung microvascular endothelium is enriched with progenitor cells that exhibit vasculogenic capacity.

Authors:  Diego F Alvarez; Lan Huang; Judy A King; M Khair ElZarrad; Mervin C Yoder; Troy Stevens
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-12-07       Impact factor: 5.464

4.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

5.  Transgenic mice with inducible dwarfism.

Authors:  E Borrelli; R A Heyman; C Arias; P E Sawchenko; R M Evans
Journal:  Nature       Date:  1989-06-15       Impact factor: 49.962

6.  Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension.

Authors:  Kentaro Hayashida; Jun Fujita; Yoshiko Miyake; Hiroshi Kawada; Kiyoshi Ando; Satoshi Ogawa; Keiichi Fukuda
Journal:  Chest       Date:  2005-05       Impact factor: 9.410

7.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

Authors:  Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-22       Impact factor: 5.464

8.  Chronic airway infection leads to angiogenesis in the pulmonary circulation.

Authors:  N Hopkins; E Cadogan; S Giles; P McLoughlin
Journal:  J Appl Physiol (1985)       Date:  2001-08

9.  Recapitulation of developing artery muscularization in pulmonary hypertension.

Authors:  Abdul Q Sheikh; Janet K Lighthouse; Daniel M Greif
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

10.  The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Authors:  Simon D Harding; Joanna L Sharman; Elena Faccenda; Chris Southan; Adam J Pawson; Sam Ireland; Alasdair J G Gray; Liam Bruce; Stephen P H Alexander; Stephen Anderton; Clare Bryant; Anthony P Davenport; Christian Doerig; Doriano Fabbro; Francesca Levi-Schaffer; Michael Spedding; Jamie A Davies
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

View more
  3 in total

1.  Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model.

Authors:  Vandana S Nikam; Sandeep Nikam; Akyl Sydykov; Katrin Ahlbrecht; Rory E Morty; Werner Seeger; Robert Voswinckel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

2.  Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system.

Authors:  Andreas Weigert; Xiang Zheng; Alina Nenzel; Kati Turkowski; Stefan Günther; Elisabeth Strack; Evelyn Sirait-Fischer; Eiman Elwakeel; Ivan M Kur; Vandana S Nikam; Chanil Valasarajan; Hauke Winter; Alexander Wissgott; Robert Voswinkel; Friedrich Grimminger; Bernhard Brüne; Werner Seeger; Soni Savai Pullamsetti; Rajkumar Savai
Journal:  Nat Commun       Date:  2022-10-14       Impact factor: 17.694

Review 3.  Progenitor/Stem Cells in Vascular Remodeling during Pulmonary Arterial Hypertension.

Authors:  France Dierick; Julien Solinc; Juliette Bignard; Florent Soubrier; Sophie Nadaud
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.